



This is an author produced version of a paper published in
Cell biology and toxicology.

This paper has been peer-reviewed and is proof-corrected, but does not
include the journal pagination.

Citation for the published paper:

Tallkvist, Jonas., Yagdiran, Yagmur., Danielsson, Louise., Oskarsson,
Agneta. (2015) A model of secreting murine mammary epithelial HC11
cells comprising endogenous Bcrp/Abcg2 expression and function. Cell
biology and toxicology. Volume: 31, Number: 2, pp 111-120.

<http://dx.doi.org/10.1007/s10565-015-9298-5>.

Access to the published version may require journal subscription.

Published with permission from: Springer.

Epsilon Open Archive <http://epsilon.slu.se>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

**A Model of Secreting Murine Mammary Epithelial HC11 Cells Comprising Endogenous
Bcrp/Abcg2 Expression and Function**

Jonas Tallkvist*, Yagmur Yagdiran, Louise Danielsson, Agneta Oskarsson

Department of Biomedical Sciences and Veterinary Public Health, Swedish University of
Agricultural Sciences, SE-750 07 Uppsala, Sweden

Running title: Bcrp/Abcg2 Mediated Transport in Mammary Epithelial Cells

*Corresponding author:

Jonas Tallkvist

Department of Biomedical Sciences and Veterinary Public Health, Swedish University of
Agricultural Sciences, SE-750 07 Uppsala, Sweden

Phone.: +46 18 673178; Email: Jonas.Tallkvist@slu.se

1 **Abstract**

2

3 Breast cancer resistance protein (Bcrp/Abcg2) and multidrug transporter 1 (Mdr1/Abcb1) are
4 efflux proteins located in the apical membrane of mammary epithelial cells (MEC). Bcrp is
5 induced in MEC during gestation and lactation, while Mdr1 is down-regulated during
6 lactation. Numerous drugs and toxic compounds are known to be actively secreted into milk
7 by Bcrp, but most chemicals have not been investigated in this respect, emphasizing the need
8 for functional Bcrp studies in an established cell line with secreting mammary epithelial cells.
9 The present study was undertaken to examine expressions of Bcrp and Mdr1 in mammary
10 epithelial HC11 cells, derived from a mid-gestational murine mammary gland. In addition,
11 Bcrp function was assessed by transport experiments with mitoxantrone (MX) in
12 undifferentiated HC11 cells, in HC11 cells subjected to *Bcrp* RNA interference (RNAi) as
13 well as in HC11 cells stimulated to differentiate by treatment with lactogenic hormones.
14 Differentiated HC11 cells organized into alveolar-resembling structures and gene expression
15 of the major milk protein β -casein was induced, whereas undifferentiated cells formed
16 monolayers with lower β -casein expression. Bcrp and Mdr1 gene and protein were expressed
17 in both undifferentiated and differentiated HC11 cells. Differentiation of HC11 cells resulted
18 in increased Bcrp protein expression, while Mdr1 gene and protein expressions were reduced.
19 The Bcrp inhibitor elacridar (GF120918) reduced secretion and increased accumulation of
20 MX in both undifferentiated and differentiated HC11 cells. Silencing of the *Bcrp* gene caused
21 an increased accumulation of MX. The results indicate that the HC11 cell model provides a
22 promising tool to investigate transport of potential Bcrp substrates in mammary epithelial
23 cells.

24

25

26

1 **Introduction**

2

3 Breast cancer resistance protein (BCRP/ABCG2) is a 72 kDa protein, composed by a single
4 N-terminal ATP binding site followed by six putative transmembrane segments, belonging to
5 the ATP binding cassette (ABC) superfamily of transporters (Doyle et al., 1998). BCRP is
6 situated in the apical membrane of epithelial cells in numerous tissues including the intestine,
7 liver, kidneys and several blood-tissue barriers where it serves to extrude its substrates and by
8 these means limiting availability and systemic exposure (Jonker et al., 2000; Maliapaard et al.,
9 2001; Zhang et al., 2004). Furthermore, BCRP is highly expressed in cancer cells where it
10 prevents the uptake of the antineoplastic drug mitoxantrone, diminishing its therapeutic effect
11 (Doyle et al., 1998; Bates et al., 2001). Thus, one important biological function of BCRP in
12 most tissues appears to comprise cellular protection and detoxification.

13

14 BCRP is also expressed in apical membrane of mammary epithelial cells (MEC) which faces
15 the alveolar lumen of the mammary glands (Jonker et al., 2005; Lindner et al., 2013). During
16 gestation and lactation BCRP is upregulated. Although the physiological role for BCRP in
17 MEC is not totally clarified the transporter has been demonstrated to actively efflux vitamin
18 B2 (riboflavin) into milk (van Herwaarden et al., 2007; Vlaming et al., 2009). Furthermore,
19 active secretion of a variety of exogenous BCRP substrates, including human and veterinary
20 drugs, environmental pollutants and other food contaminants, into milk have been
21 demonstrated (Jonker et al., 2005; van Herwaarden et al., 2007; Mealey 2012). Expression
22 and function of BCRP can also be influenced by chemicals. Thus, flavonoids and
23 isoflavonoids, present in many food and feed plants, inhibit BCRP and may thus decrease
24 milk secretion of BCRP substrates (Zhang et al., 2004; Morris and Zhang, 2006). On the other
25 hand, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD) and the fungicide prochloraz induce

1 BCRP in mammary epithelial cells and may increase the milk excretion of BCRP substrates
2 (Halwachs et al., 2013).

3

4 The exposure of hazardous compounds via milk in sensitive population groups is of high
5 concern in risk assessment and there is a need for methods to screen for chemicals with active
6 transport into milk and to further investigate the underlying mechanisms. Transfected Madin-
7 Darby Canine Kidney II (MDCKII) epithelial cells stably expressing human, bovine and
8 caprine BCRP have been used to identify new BCRP substrates as well as the impact of the
9 common Y581S point mutation in BCRP function (Jonker et al, 2000; Real et al., 2011;
10 Wassermann et al., 2013; Halwachs et al., 2014). However, expression and function of
11 endogenous BCRP in non-tumorigenic mammary epithelial cell lines has not yet been
12 examined. Such a model would be valuable for studies on BCRP expression and function after
13 treatment with xenobiotics.

14

15 HC11 cells are non-tumorigenic mammary epithelial cells derived from the mouse mammary
16 epithelial cell line COMMA-1D collected from the mammary glands of Balb/c mice during
17 mid-gestation (Danielson et al, 1984). The HC11 cells express functional prolactin receptors
18 and have been used as a model to examine the progression of mammary epithelial
19 differentiation to a secreting phenotype (Ball et al., 1988; Marte et al., 1994; Desrivières et al.,
20 2003). In addition, the HC11 cell model has been applied to characterize transporters
21 implicated in the flux of zinc, copper, sodium and calcium across the membranes of the
22 lactating mammary epithelium (Kelleher and Lönnerdal, 2005, 2006; Boyd and Náráy-Fejes-
23 Tóth, 2007; Öhrvik et al, 2010; McCormick and Kelleher, 2012; Ross et al., 2013). However,
24 no studies have so far been directed to investigating expression and function of ABC
25 transporters in HC11 cells.

1

2 The present study was undertaken to examine endogenous expressions of Bcrp and Mdr1 in
3 mammary epithelial HC11 cells. In addition, transport experiments with the BCRP substrate
4 mitoxantrone (MX) were carried out in undifferentiated HC11 cells, in HC11 cells subjected
5 to *Bcrp* RNAi as well as in HC11 cells stimulated to differentiate by treatment with lactogenic
6 hormones.

1 **Materials and Methods**

2

3 *Cells*

4 HC11 cells of passage 26 was a generous gift from Dr Shannon Kelleher, Department of
5 Nutritional Sciences, Pennsylvania State University, USA and was cultured by permission of
6 Dr Bernd Groner, Institute for Biomedical Research, Frankfurt, Germany. The cells were
7 expanded in T75 tissue culture flasks at 37°C in 15 ml of sterile filtered RPMI 1640 medium
8 containing L-glutamin and 25 mM HEPES (Invitrogen) supplemented with 50 µg/ml
9 gentamicin, 5 µg/ml bovine insulin, 10 ng/ml epidermal growth factor (EGF), 7.5% NaHCO₃
10 and 10% heat-inactivated foetal bovine serum (FBS) in an atmosphere of 95% air and 5%
11 CO₂ in 95% relative humidity. The cell culture medium was changed every 2-3 days and cells
12 between passages 28-33 were harvested at 80-90% confluency. HC11 cells were seeded at a
13 density of 50,000 cells/cm² in 6-well plates and cultured to confluency. Two days
14 postconfluency cells were cultured for an additional 24 h in the FBS-containing RPMI 1640
15 medium described above but without EGF. Differentiation of the HC11 cells was then
16 achieved by culturing the cells for 72 h in EGF- and FBS-free RPMI 1640 medium
17 supplemented with 1 µg/ml prolactin and 1 µM cortisol as described (Desrivières et al., 2003).
18 Undifferentiated HC11 cells (controls) were cultured in parallel with the FBS- and EGF-
19 containing RPMI 1640 medium. To study the cellular organization approximately 800,000
20 cells in a volume of 400 µl were seeded per chamber on slides (Lab-Tec® chamber slide™
21 system, Nalge Nunc International). In 4 of the 8 chambers on each slide (n=3) the cells were
22 allowed to differentiate for 3 days as described above whereas the other 4 served as
23 undifferentiated controls. The cells were fixed in 4°C acetone for 5 min and then rinsed with
24 1XPBS, pH 7.4 prior to nuclei staining with hematoxylin.

25

1 *Quantitative real-time RT-PCR*

2 Following incubation of the HC11 cells in either control or differentiating culture medium as
3 described above or transfection medium as described below the cells were rinsed with 1XPBS
4 and the RNA was isolated by applying NucleoSpin[®]RNA II Columns with DNaseI according
5 to the instructions of the manufacturer (BD Biosciences). As a quality control of primers used
6 in the real-time RT-PCR with cellular RNA, primers were tested on RNA from mouse
7 mammary gland tissues taken at different lactation stages. HARLAN NMRI-mice were given
8 a standard pellet diet and tap water ad libitum under standard conditions of temperature and
9 light. Animals were killed by cervical dislocation and mammary glands from pregnant
10 (gestation days 13 and 18), lactating (lactation days 2 and 9) and weaning (weaning day 2)
11 mice were rapidly excised, placed in RNAlater (Invitrogen), snap-frozen in liquid nitrogen
12 and stored at -70°C pending isolation of total RNA. Tissues were homogenized in 10 volumes
13 of RA1 buffer as recommended by the manufacturer (BD Biosciences) and RNA isolated with
14 NucleoSpin[®]RNA II Columns with DNaseI as described above. Animal experiments were
15 ethically approved (permit no. 2012-15-2934-00587) and carried out in collaboration with Dr
16 Christopher Knight, at the Department of Health and Medical Sciences, University of
17 Copenhagen, Denmark. Total RNA from mammary glands was quantitated by use of the
18 RiboGreen protocol with DNase I (Invitrogen) and RNA samples were stored at -70°C until
19 used. Quantitative gene expression was measured by real-time RT-PCR by applying a
20 Rotorgene, RG3000 (Corbett Research) as described (Öhrvik et al., 2010) in the presence of
21 400 nM forward and reverse primers in a total volume of 12.5 µl (Table 1).

22

23 *Western Blot*

24 HC11 cells were seeded at a density of 50,000 cells/cm² in a total of 4 separate T75 tissue
25 culture flasks and cultured and differentiated as described above prior to harvesting by

1 trypsination and homogenization of the obtained cell pellet in 5 volumes of RIPA-lysis buffer.
2 HC11 cells in 2 T75 flasks were differentiated as described above while the cells in the other
3 2 flasks served as undifferentiated controls. The homogenization of the HC11 cells was
4 carried out in 1.5 ml Eppendorf tubes by thorough pipetting. Homogenates were incubated on
5 ice for 30 min and then centrifuged at 16,000Xg for 30 min at 4°C and supernatant protein
6 concentrations determined as described (McKie et al., 2000). 20-50 µg of cellular protein was
7 separated on a 10% Tris-Glycine polyacrylamide gel under reducing conditions and blotted to
8 nitrocellulose as described (Öhrvik et al., 2007). Three nitrocellulose membranes with
9 proteins from each T75 flasks were incubated in blocking buffer (5% nonfat dry milk powder
10 in Tris buffered saline containing 0.05% Tween 20 (TBS-T) over night at 4°C. Membranes
11 were then hybridized with a primary BCRP antibody (BXP-53, Abcam) diluted 1:100 or
12 primary MDR1 antibody (JSB-1, Abcam) diluted 1:200 in TBS-T. The primary antibodies
13 were detected by Horse Radish Peroxidase-conjugated secondary antibodies (ab6728, Abcam)
14 diluted 1:7500 in TBS-T. In order to normalize the intensities of the bands, all the membranes
15 were stripped at 60°C with buffer containing 62.5 mM Tris-HCl, 100 mM 2-mercaptoethanol,
16 2% SDS and then hybridized with anti-Tubulin antibody (YOL1/34) diluted 1:3000. Horse
17 Radish Peroxidase-conjugated secondary antibodies to tubulin (ab6734, Abcam) diluted
18 1:5000 in TBS-T. HRP was detected by ECL Advance (GE Healthcare) and the intensities of
19 the obtained bands quantitated as described (Öhrvik et al. 2010). As a quality control of the
20 antibodies used in the Western with cellular protein, they were tested on protein isolated from
21 mammary gland of pregnant and lactating mice.

22

23 *Bcrp RNAi*

24 Prior to the *Bcrp* RNAi of the HC11 cells optimization of transfection efficiency was
25 performed by incubating various densities of HC11 cells with either siTOX Transfection

1 Control (Dharmacon) or a non-targeting negative control (On-Target plus siControl Non-
2 Targeting Pool, Dharmacon) in the presence of various dilutions of DharmaFECT siRNA
3 Transfection Reagents 1-4, as recommended by the manufacturer (Dharmacon). ATP levels
4 were measured to check viability of the HC11 cells following each set of transfection
5 condition by applying the ATP Determination Kit (Invitrogen), with formaldehyde-treated
6 cells as positive controls. Firefly luciferase induced chemiluminescence of cellular ATP was
7 measured on a Victor² 1420 multilabel counter (PerkinElmer). Following the various
8 transfection conditions the one resulting in the lowest viability following treatment with
9 siTOX Transfection Control reagent and the highest viability following treatment with the
10 On-Target plus siControl Non-Targeting Pool was selected. Following this optimization of
11 transfection efficiency cyclophilin B siRNA transfection was performed under the optimized
12 condition by the use of siControl cyclophilin B siRNA (targeting mouse cyclophilin,
13 accession number NM_011149) according to the instructions of the manufacturer. The
14 silencing of the cyclophilin B gene was measured by quantitative real-time RT-PCR with
15 specific primers (Table 1) as described above. After successful silencing of cyclophilin B the
16 optimized siRNA transfection protocol was adopted to silence *Bcrp* expression. HC11 cells
17 were harvested in antibiotic-free RPMI 1640 medium and seeded into 6-well tissue culture
18 plates at a density of 8,300 cells/cm². After incubation for 24 h at 37°C the medium was
19 replaced with 2 ml of transfection medium (Opti-MEM) containing 100 nM On-Target plus
20 SMART pool (targeting mouse BCRP, accession number NM_011920) and DharmaFECT 1
21 Transfection Reagent diluted 1:4. Mock transfected cells were incubated as described above
22 with 2 ml Opti-MEM containing 100 nM On-Target plus siControl Non-Targeting RNA
23 duplexes. Following transfection for 48 h at 37°C the HC11 cells were either subjected to
24 RNA isolation for quantitative gene expression of *Bcrp* by real-time RT-PCR or transport
25 experiments with MX (as described below).

1

2 *Transport experiments*

3 Prior to the experiments HC11 cells were seeded in 12 well plates at a density of 50,000
4 cells/cm² and cultured and treated as described above. MX (Sigma) was used to examine the
5 function of BCRP in the HC11 cells using ³H-MX, with a specific radioactivity of 4 Ci/mmol,
6 as tracer (Moravek Biochemicals). It has previously been demonstrated that BCRP mediated
7 transport of MX is reduced by GF120918 (de Bruin et al., 1999). Accumulation studies with
8 MX were performed as follows. HC11 cells were rinsed with 2 x 1.5 ml of 37°C Hank's
9 Balanced Salt Solution with CaCl₂ and MgCl₂ (Invitrogen), pH 7.4 containing 25 mM N-(2-
10 hydroxyethyl) piperazine-N'-(2-ethanesulfonic) acid (HEPES, Sigma-Aldrich) (HBSS) and
11 then pre-incubated for 30 min at 37° in 1.5 ml HBSS. After pre-incubation the HC11 cells
12 were incubated at 37°C for 60 min with 37°C HBSS containing 1 μM MX supplemented 3000
13 Bq ³H-MX/ml. Experiments including inhibitor were performed in HBSS, containing 1 μM of
14 GF120918 during the 60 min incubation period. At the end of the experiment the HC11-cells
15 were rinsed with 3 x 1.5 ml ice-cold HBSS and thereafter lysed by adding 1 ml 0.5 M NaOH
16 to each well. The MX concentration in the HC11 cells was then calculated from the
17 radioactivity measurement by β-spectrometry using a 1900 CA Tri-Carb[®] Liquid Scintillation
18 Analyzer (Packard Instruments). An aliquot of the cell lysate was used for protein
19 determination by applying the BCA-method (as described above).

20

21 To study secretion of MX HC11 cells were preincubated as described above and then
22 incubated with 1 μM MX supplemented 3000 Bq ³H-MX/ml at 37°C for 60 min. After this
23 loading period the incubation medium was discarded and the HC11 cells were rinsed with 2 x
24 1.5 ml 37°C HBSS. After the washes 1.5 ml of 37°C HBSS with or without 1 μM GF120918
25 was added to the wells followed by incubation at 37°C for 45 min. At the end of the secretion

1 experiment the HBSS was sampled and MX concentrations measured by β -spectrometry as
2 described above. Both accumulation and secretion of MX was normalized to total cellular
3 protein of the HC11 cells. Prior to the transport experiments potential cellular toxicity of the
4 MX and GF120918 was assessed by measuring cellular ATP levels as described above or
5 leakage of lactate dehydrogenase (LDH) as described previously (Aspenström-Fagerlund et
6 al., 2007). No effects in ATP- or LDH-levels were detected in the experimental conditions
7 and MX and GF120918 concentrations used in the present study indicating that the observed
8 effects in accumulation and secretion were not a result of cytotoxicity induced by of these
9 chemical compounds.

10

11 *Statistics*

12 Statistical analysis was performed using Statview 4.1 software for PC. Kruskal-Wallis was
13 used to detect any significant differences in the data. Mann-Whitney was applied to examine
14 statistically significant differences between two groups. The level of significance was set at p
15 ≤ 0.05 .

16

1 **Results**

2

3 *Cellular organization*

4 The morphology of the HC11 cells was affected by the differentiation procedure. The
5 differentiated cells showed a characteristic pattern with alveolar resembling structures
6 including lumina, whereas the undifferentiated cells were organized as a monolayer (Figure
7 1).

8

9 *mRNA expressions*

10 Gene expression of β -casein (*Csn2*) and *Bcrp* was detected in both undifferentiated and
11 differentiated HC11 cells. A statistically significant induction of β -casein gene expression
12 was observed in the differentiated HC11 cells as compared to the undifferentiated controls
13 (Figure 1a). Thus, the relative β -casein gene expression was increased 2-fold in the
14 differentiated as compared to the undifferentiated HC11 cells (Figure 1a). The relative *Bcrp*
15 gene expression was at a similar level in undifferentiated and differentiated HC11 cells
16 (Figure 2a). A statistically significant 2-fold reduction in *Mdr1* gene expression was observed
17 in the differentiated HC11 as compared to the undifferentiated ones (Figure 2b).

18

19 *Protein expressions*

20 *Bcrp* and *Mdr1*-protein was detected in both undifferentiated and differentiated HC11 cells
21 (Figure 3). Tubulin normalized *Bcrp* protein expression was up-regulated and *Mdr1* protein
22 expression down-regulated in the differentiated as compared to the undifferentiated HC11
23 cells (Figure 3). Quantification of *Bcrp* and *Mdr1* protein levels in differentiated and
24 undifferentiated HC11 cells as performed in two separate experiments with triplicate analyses
25 did not show any overlaps in protein levels.

1

2 *Bcrp silencing*

3 To test the function of our optimized transfection efficiency conditions RNAi was initially
4 performed with the house-keeping gene cyclophilin B. Our results showed that almost a 90%
5 down-regulation of the cyclophilin B gene expression was obtained (Figure 4). Using the
6 same protocol with *Bcrp* siRNA-duplexes *Bcrp*-transcript levels were reduced to the same
7 extent as cyclophilin (Figure 4).

8

9 *Transport experiments*

10 The transport experiments with ³H-MX showed that the accumulation was increased in both
11 undifferentiated and differentiated HC11 cells simultaneously incubated with GF120918
12 (Figure 5a). Thus, in the presence of the BCRP inhibitor the accumulation of MX increased
13 with about 21% in the undifferentiated HC11 cells and with about 36% in the differentiated
14 ones. Our results also showed that the accumulation of MX was higher in the differentiated
15 HC11 cells as compared to the undifferentiated controls (Figure 5a). The presence of the
16 inhibitor GF120918 also resulted in a decreased secretion of MX from the loaded HC11 cells
17 (Figure 5b). The secretion of MX was reduced to about 65% in the presence of GF120918 in
18 undifferentiated HC11 cells and to about 70% in the differentiated ones. The results obtained
19 in the transport experiments with ³H-MX showed that the accumulation of MX in HC11 cells
20 increased 2-fold by *Bcrp* RNAi as compared to the MX accumulation in the mock transfected
21 HC11 cells (Figure 5a).

22

1 **Discussion**

2

3 The results obtained in the present investigation demonstrate for the first time that both Bcrp
4 and Mdr1 are expressed in the HC11 cells and are up- and downregulated, respectively by
5 differentiation as in mammary epithelial cells *in vivo* during lactation. Thus, whereas Bcrp
6 protein levels were increased in HC11 cells differentiated into a secreting phenotype, Mdr1
7 protein levels were decreased. These results are in line with the *in vivo* findings that BCRP is
8 up-regulated and MDR1 down-regulated in lactating mammary glands in various species
9 (Alcorn et al., 2002; Jonker et al., 2005; Gilchrist and Alcorn, 2009) and suggest that the
10 HC11 model can be used to both assess function of endogenous Bcrp and to detect new
11 substrates as well as inducers and inhibitors of this transporter.

12

13 HC11 cells have been used as a model for studies on hormonal regulation of mammary
14 epithelial cell differentiation as well as milk protein gene expression and secretion (Wartmann
15 et al., 1996; Desrivières et al., 2003; Kabotyanski et al., 2006). Furthermore, HC11 cells have
16 been applied to examine the impact of toxic compounds on lactating mammary cells (Öhrvik
17 et al., 2010) and also to characterize some transporters belonging to the Solute Carrier (SLC)
18 family and ion channels, which are implicated in the flux of magnesium, zinc, copper and
19 calcium across the membranes of the lactating mammary epithelium (Kelleher and Lönnerdal,
20 2005, 2006; Boyd and Náráy-Fejes-Tóth, 2007; Öhrvik et al, 2010; Wolf et al., 2010;
21 McCormick and Kelleher, 2012; Ross et al., 2013). However, the HC11 cell model has not yet
22 been used to characterize expression and/or function of ATP Binding Cassette (ABC)
23 transporters. The localization of both BCRP and MDR1 in the apical membranes of MECs in
24 combination with the promiscuity of these active transporters has risen considerable concern
25 from public health, food safety, and regulatory perspectives about the presence of drugs and

1 toxic compounds in milk both for breast fed infants as well as for consumers of dairy products
2 (Wassermann et al., 2013).

3

4 Herein, we showed that *Bcrp* gene expression was at a similar level in undifferentiated and
5 differentiated HC11 cells whereas *Mdr1* transcript levels were reduced in the differentiated
6 ones. The reason for the lack of induction of *Bcrp* mRNA in the HC11 cells by lactogenic
7 stimulation in the present investigation is unknown. However, one possible explanation may
8 be that the HC11 cells originally derive from mammary tissue of BALB/c mice during
9 gestation when *Bcrp* transcripts levels are induced to a stage where no further increases in
10 gene expression occurs (Danielsson et al., 1984; Jonker et al., 2005). In support of this,
11 silencing of *Bcrp* gene expression in undifferentiated HC11 cells resulted in a marked
12 decrease in Bcrp function as assessed by increased MX accumulation, which probably would
13 not have been possible to demonstrate if the endogenous Bcrp expression in the control cells
14 was at a baseline level.

15

16 In the present investigation the HC11 cells differentiated by treatment with prolactin and
17 cortisol were organized into alveolar-like structures with lumina resembling the organization
18 of the mammary epithelial cells observed in the mammary glands *in vivo* during lactation
19 (Burgoyne and Duncan, 1998; Richert et al., 2000).. Beside the changes in cellular
20 organization by lactogenic stimulation β -casein gene expression was also induced in the
21 HC11 cells. It has previously been demonstrated that β -casein responds to prolactin in HC11
22 cells (Ball et al., 1988) and that synthesis occurs in rodent MEC *in vivo* and that the
23 abundance of this milk protein increases during gestation and peaks at mid-lactation
24 (Robinson et al., 1995; Burgoyne and Duncan, 1998; Richert et al., 2000; McManaman and
25 Neville, 2003). Thus, reorganization of HC11 cells into alveolar-resembling formations in

1 combination with an increased β -casein gene expression by lactogenic stimulation appears to
2 be reliable markers of a secreting phenotype. Based on the results obtained in the present
3 study reduced gene and protein expression of Mdr1 as well as increased expression of Bcrp
4 protein may also be used as secretory markers of the HC11 cells.

5
6 Our results showed that the net accumulation of MX was higher in the differentiated HC11
7 cells as compared to the undifferentiated controls despite an apparent higher expression of
8 Bcrp. This may, at least in part, be explained by a reduced expression of Mdr1. Although MX
9 extrusion is predominantly mediated by Bcrp it has been demonstrated that MX can be
10 transported to the extracellular compartment by Mdr1 although this transporter harbors less
11 substrate specificity for MX than Bcrp and thus requires higher substrate concentrations
12 (Ahmed-Belkacem, 2005; Rautio et al., 2006; Kodaira et al., 2010). Numerous SLC
13 transporters, comprising both organic cation transporters (OCTs) and organic anion
14 polypeptide transporters (OATPs), in MECs are affected at the transcriptional level by
15 lactogenic stimulation (Alcorn et al., 2002; Gilchrist and Alcorn, 2010) including some with
16 potential MX affinity. It may, hence, be possible that the increased accumulation of MX in the
17 HC11 cells featuring a secretory phenotype as opposed to the undifferentiated ones is not only
18 connected to the reduced expression of Mdr1 observed herein, but also to a concerted action
19 of a number of other transporters including Oct or/and Oatp transporters.

20
21 Madine-Darby Canine Kidney II (MDCK II), human intestinal epithelial cells (Caco-2),
22 human breast adenocarcinoma cells (MCF7), human choriocarcinoma cells (BeWo) and
23 human bone osteosarcoma cells (SAOS-2) constitute examples of models used to characterize
24 the function and substrate specificities of efflux proteins such as BCRP (Doyle et al., 1998;
25 Jonker et al., 2000; Ceckova et al., 2006; Matsson et al., 2007; Li et al., 2011; Wasserman et

1 al., 2013). However, cancer cell lines and non-tumorigenic cell lines deriving from tissues
2 other than the alveolar lining of the mammary glands harbor different sets of transporter
3 protein panels at both the apical and basolateral membranes which may affect secretion and
4 net accumulation of substrates may therefore differ (Krajci 2013). As expected by a Bcrp
5 inhibitor, GF120918 treatment of HC11 cells decreased both net accumulation and secretion
6 of MX. This corroborates our suggestion that the HC11 cells can be used for assessing
7 transport of potential Bcrp substrates across the mammary epithelium.

8

9 The results obtained in the present investigation demonstrate for the first time that the murine
10 mammary epithelial HC11 cells feature endogenous Bcrp and Mdr1 expression and that the
11 expressions of these transporter proteins appear to respond to treatment with lactogenic
12 hormones in a corresponding manner as mammary epithelial cells *in vivo* during lactation.
13 Based on these findings it can be concluded that the HC11 cells comprise a promising tool to
14 assess the impact of drugs and other chemicals on endogenous BCRP function.

15

16

17

1 **Acknowledgements**

2 This study was supported by the Swedish Research Council for Environment, Agricultural
3 Sciences and Spatial Planning (Formas).

4

5 **Conflict of Interest**

6 There are no conflicts of interest regarding this manuscript and the authors have nothing to
7 disclose.

8

1 **References**

2

3 Ahmed-Belkacem A, Pozza A, Munoz-Martinez F, Bates SE, Castanys S, Gamarro F et al.
4 Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and
5 specific inhibitors of breast cancer resistance protein ABCG2. *Cancer Res* 2005;65:4852-60.

6

7 Alcorn J, Lu X, Moscow A, McNamara PJ. Transporter gene expression in lactating and
8 nonlactating human mammary epithelial cells using real-time reverse transcription-
9 polymerase chain reaction. *J Pharmacol Exp Ther* 2002;303:487-96.

10

11 Aspenström-Fagerlund B, Ring L, Aspenström P, Tallkvist J, Ilbäck NG, Glynn A. Oleic acid
12 and docosahexanoic acid cause an increase in the paracellular absorption of hydrophilic
13 compounds in an experimental model of human absorptive enterocytes. *Toxicology*
14 2007;237:12-23.

15

16 Ball RK, Friis RR, Schoenenberger CA, Doppler W, Groner B. Prolactin regulation of β -
17 casein gene expression and of a cytosolic 120-kd protein in a cloned mouse mammary
18 epithelial cell line. *Embo J* 1988;7:2089-95.

19

20 Bates SE, Robey R, Miyake K, Rao K, Ross DD, Litman T. The role of half-transporters in
21 multidrug resistance. *J Bioenerg Biomembr* 2001;33:503-11.

22

23 [Boyd C, Náray-Fejes-Tóth A.](#) Steroid-mediated regulation of the epithelial sodium channel
24 subunits in mammary epithelial cells. *Endocrinology* 2007;148:3958-67.

25

1 Burgoyne RD, Duncan JS. Secretion of milk proteins. [J Mammary Gland Biol Neoplasia](#)
2 1998;3:275-86.
3
4 Ceckova M, Libra A, Pavek P, Nachtigal P, Brabec M, Fuchs R et al. Expression and
5 functional activity of breast cancer resistance protein (BCRP/ABCG2) transporter in the
6 human choriocarcinoma cell line BeWo. *Clin Exp Pharmacol Physiol* 2006;33:58-65.
7
8 Danielsson KG, Oborn CJ, Durban EM, Butel JS, Medina D. Epithelial mouse mammary cell
9 line exhibiting normal morphogenesis in vivo and functional differentiation in vitro. *PNAS*
10 1984;81:3756-60.

11 de Bruin M, Miyake K, Litman T, Robey R, Bates SE. Reversal of resistance by GF120918 in
12 cell lines expressing the ABC half-transporter, MXR. *Cancer Lett* 1999;146:117-28.

13 [Desrivières S](#), [Prinz T](#), [Castro-Palomino Laria N](#), [Meyer M](#), [Boehm G](#), [Bauer U](#) et al.
14 Comparative proteomic analysis of proliferating and functionally differentiated mammary
15 epithelial cells. *Mol Cell Proteomics* 2003;2:1039-54.
16
17 [Doyle LA](#), [Yang W](#), [Abruzzo LV](#), [Krogmann T](#), [Gao Y](#), [Rishi AK](#) et al. A multidrug
18 resistance transporter from human MCF-7 breast cancer cells. *PNAS USA* 1998;95:15665-70.
19
20 Gilchrist SE, Alcorn J. Lactation stage-dependent expression of transporters in rat whole
21 mammary gland and primary mammary epithelial organoids. *Fundam Clin Pharmacol*
22 2010;24:205-14.
23

1 Halwachs S, Wassermann L, Lindner S, Zizzadoro C, Honscha W. Fungicide prochloraz and
2 environmental pollutant dioxin induce the ABCG2 transporter in bovine mammary epithelial
3 cells by the arylhydrocarbon receptor signalling pathway. *Toxicol Sci* 2013;131:491-501.

4

5 Halwachs S, Wassermann L, Honscha W. A novel MDCKII in vitro model for assessing
6 ABCG2 transport activity in the caprine mammary gland by environmental pollutants and
7 pesticides. *Toxicol In Vitro* 2014;28:432-41.

8

9 Jonker JW, Smit JW, Brinkhuis RF, Maliepard M, Beijnen JH, Schellens JH et al. Role of
10 breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. *J Natl*
11 *Cancer Inst* 2000;92:1651-6.

12

13 Jonker JW, Merino G, Musters S, Herwaarden AE, Bolscher E, Wagenaar E et al. The breast
14 cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins
15 into milk. *Nat Med* 2005;11:127-29.

16

17 Kabotyanski EB, Huetter M, Xian W, Rijnkels M, Rosen JM. Integration of prolactin and
18 glucocorticoid signalling at the beta-casein promoter and enhancer by ordered recruitment of
19 specific transcription factors and chromatin modifiers. *Mol Endocrinol* 2006;20:2355-68.

20

21 Kelleher SL, Lönnerdal B. Zip3 plays a major role in zinc uptake into mammary epithelial
22 cells and is regulated by prolactin. *Am J Physiol Cell Physiol* 2005;288:1042-47.

23

1 [Kelleher SL, Lönnerdal B](#). Mammary gland copper transport is stimulated by prolactin
2 through alterations in Ctr1 and Atp7A localization. *Am J Physiol Regul Integr Comp Physiol*
3 2006;291:1181-91.
4
5 Kodaira H, Kusuhara H, Ushiki J, Fuse E, Sugiyama Y. Kinetic analysis of the cooperation of
6 P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting
7 the brain and testis penetration of erlotinib, flavopiridol and mitoxantrone. *J Pharmacol Exp*
8 *Ther* 2010;333:788-96.
9
10 Krajci P. Drug-transporter interaction testing in drug discovery and development. *World J*
11 *Pharmacol* 2013;2:35-46.
12
13
14 Li J, Volpe DA, Wang Y, Zhang W, Bode C, Owen A et al. Use of transporter knockdown
15 Caco-2 cells to investigate the in vitro efflux of statin drugs. *Drug Metab Dispos*
16 2011;39:1196-202.
17
18 Lindner S, Halwachs S, Wassermann L, Honscha W. Expression and subcellular localization
19 of efflux transporter ABCG2/BCRP in important tissue barriers of lactating dairy cows, sheep
20 and goats. *J Vet Pharmacol Ther* 2013;36:562-70.
21
22 Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH et
23 al. Subcellular localization and distribution of the breast cancer resistance protein transporter
24 in normal human tissues. *Cancer Res* 2001;61:3458-64.
25

1 Marte BM, Meyer T, Stabel S, Standke GIR, Jaken S, Fabbro D et al. Protein kinase C and
2 mammary cell differentiation: involvement of protein kinase C alpha in the induction of beta-
3 casein expression. *Cell Growth Differ* 1994;5:239-47.
4

5 Matsson P, Englund G, Ahlin G, Bergström CAS, Norinder U, Artursson P. A global drug
6 inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance
7 protein (ABCG2). *J Pharmacol Exp Ther* 2007;323:19-30.
8

9 McCormick NH, Kelleher SL. ZnT4 provides zinc to zinc-dependent proteins in the trans-
10 Golgi network critical for cell function and Zn export in mammary epithelial cells. *Am J*
11 *Physiol Cell Physiol* 2012;303:291-7.
12

13 McKie AT, Marciani P, Rolfs A, Brennan K, Wehr K, Barrow D et al. A novel duodenal iron-
14 regulated transporter, IREG, implicated in the basolateral transfer of iron to the circulation.
15 *Mol Cell* 2000;5:299-309.
16

17 McManaman JL, Neville MC. Mammary physiology and milk secretion. *Adv Drug Deliv Rev*
18 2003;55:629-41.
19

20 Mealey KL. ABCG2 transporter: therapeutic and physiologic implications in veterinary
21 species. *J Vet Pharmacol Therap* 2012;35:105-12.
22

23 Morris ME, Zhang S. Flavonoid – drug interactions: Effects of flavonoid on ABC
24 transporters. *Life Sci* 2006; 78; 2116-30.
25

1 Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR et al. In vitro p-
2 glycoprotein inhibition assays for assessment of clinical drug interaction potential of new
3 drug candidates: a recommendation for probe substrates. *Drug Metab Dispos* 2006;34:786-92.
4

5 Real R, González-Lobato L, Baro MF, Valbuena S, de la Fuente A, Prieto JG et al. Analysis
6 of the effect of the bovine adenosine triphosphate-binding cassette transporter G2 single
7 nucleotide polymorphism Y581S on transcellular transport of veterinary drugs using new cell
8 culture models. *J Anim Sci* 2011;89:4325-38.
9

10 Richert MM, Schwertfeger KL, Ryder JW, Anderson SM. An atlas of mouse mammary gland
11 development. [J Mammary Gland Biol Neoplasia](#) 2000;5:227-241.
12

13 Robinson GW, McKnight RA, Smith GH, Hennighausen L. Mammary epithelial cells
14 undergo secretory differentiation in cycling virgins but require pregnancy for the
15 establishment of terminal differentiation. *Development* 1995;121:2079-90.
16

17 Ross DG, Smart CE, Azimi I, Roberts-Thomson SJ, Monteith GR. Assessment of ORAI1-
18 mediated basal calcium influx in mammary epithelial cells. *BMC Cell Biol* 2013;14:57.
19 Doi: 10.11186/1471-2121-14-57.
20

21 van Herwaarden AE, Wagenaar E, Merino G, Jonker JW, Rosing H, Beijnen JH et al.
22 Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin
23 B2) into milk. *Mol Cell Biol* 2007;27:1247-53.
24

1 Vlaming MLH, Lagas JS, Schinkel AH. Physiological and pharmacological roles of
2 ABCG2(BCRP): recent findings in Abcg2 knockout mice. *Adv Drug Deliv Rev* 2009;61:14-
3 25.
4
5 Wartmann M, Cella N, Hofer P, Groner B, Liu X, Hennighausen L et al. Lactogenic hormone
6 activation of Stat5 and transcription of the beta-casein gene in mammary epithelial cells is
7 independent of p42 ERK mitogen-activated protein kinase activity. *J Biol Chem*
8 1996;271:31863-68.
9
10 Wassermann L, Halwachs S, Baumann D, Schaefer I, Seibel P, Honscha W. Assessment of
11 ABCG2-mediated transport of xenobiotics across the blood-milk barrier of dairy animals
12 using a new MDCKII in vitro model. *Arch Toxicol* 2013;87:1671-82.
13
14 Wolf FI, Trapani V, Simonacci M, Mastrototaro L, Cittadini A, Schweigel M. Modulation of
15 TRPM6 and Na(+)/Mg(2+) exchange in mammary epithelial cells in response to variations of
16 magnesium availability. *J Cell Physiol* 2010; 222:374-81.
17
18 Zhang S, Yang X, Morris ME. Flavonoids are inhibitors of breast cancer resistance protein
19 (ABCG2)-mediated transport. *Mol Pharmacol* 2004;65:1208-16.
20
21 [Öhrvik H, Oskarsson A, Lundh T, Skerfving S, Tallkvist J.](#) Impact of iron status on cadmium
22 uptake in suckling piglets. *Toxicology* 2007;240:15-24.
23

- 1 Öhrvik H, Ullerås E, Oskarsson A, Tallkvist J. Effects of cadmium on calcium transporter
- 2 SPCA, calcium homeostasis and beta-casein expression in the murine mammary epithelium.
- 3 Tox Lett 2010;201:80-85.
- 4
- 5

1 **Table 1.** Exon-spanning oligonucleotide primers used for quantitative gene expression
2 analyses by real-time RT-PCR.

3

Gene	Primer Sequences
β-casein	5'-CTTAACCCCACCGTCCAAT-3' (forward) 5'-AGCATGATCCAAAGGTGAAAA-3' (reverse)
<i>Bcrp/Abcg2</i>	5'-CGCAGAAGGAGATGTGTT-3' (forward) 5'-TTGGATCTTTCCTTGCTGCT-3' (reverse)
<i>Mdr1/Abcb1</i>	5'-GCTGTTAAGGAAGCCAATGC-3' (forward) 5'-AGCAATGGCGATTCTCTGGTT-3' (reverse)
Cyclophilin B	5'-GCGCAATATGAAGGTGCTCT-3' (forward) 5'-GAAGTCTCCACCCTGGATCA-3' (reverse)

4

5

1 **Legends to the figures**

2

3 **Figure 1.** a. Cellular organization of undifferentiated and differentiated HC11 cells as
4 described in Materials and Methods. Undifferentiated HC11 cells not stimulated with
5 lactogenic hormones are organized as monolayers (left). Differentiated cells treated with
6 prolactin and hydrocortisone are formatted in alveolar-resembling structures with alveolar
7 lumina (right). b. Relative β -casein gene expression in undifferentiated and differentiated
8 HC11 cells, as described in Materials and Methods. The data are presented as means \pm SD of
9 6 samples from 2 separate experiments. *Statistically significant different as compared to
10 undifferentiated controls, $p \leq 0.05$.

11

12 **Figure 2.** Relative gene expression of *Bcrp* (a) and *Mdr1* (b) in undifferentiated and
13 differentiated HC11 cells, as described in Materials and Methods. The data are presented as
14 means \pm SD of 6 samples from 2 separate experiments. *Statistically significant different as
15 compared to undifferentiated controls $p \leq 0.05$.

16

17 **Figure 3.** Protein expression of BCRP (a) and MDR1 (b) in undifferentiated and
18 differentiated HC11 cells, normalized to tubulin expression as described in Materials and
19 Methods. The data represent BCRP and MDR1 protein expression in HC11 cell lysates
20 obtained in two separate experiments, each comprising three membranes per protein
21 expressed as relative means and ranges.

22

23 **Figure 4.** Relative gene expressions of cyclophilin B and *Bcrp* in HC11 cells subjected to
24 RNA interference (RNAi). The data are presented as means \pm SD of 3-5 samples obtained
25 from 2 separate experiments. * Statistically significant as compared to untransfected controls

1 (Opti-MEM) and mock transfected cells (Opti-MEM containing Lipid 1 diluted 1:4 and non-
2 targeting RNA duplexes) as described in Materials and Methods, $p \leq 0.05$.

3

4 **Figure 5.** Accumulation (a) and secretion (b) of ^3H -mitoxantrone in undifferentiated (No) or ,
5 differentiated (Yes) HC11 cells, treated with the BCRP inhibitor GF120918, and in mock
6 transfected (mock) and *Bcrp* RNAi treated (Bcrp RNAi) HC11 cells, as described in Material
7 and Methods. The data are presented as means \pm SD of 6-12 samples and expressed as pmol
8 mitoxantrone/mg cellular protein as described in Materials and Methods. Statistically
9 significant differences between groups are indicated by links between the columns (* $p \leq 0.05$;
10 ** $p \leq 0.01$).

11

12

13

14


15

1 **Figure 1.**


2

3

a



b



4

5

6

7

8

9

10

11

12


13

14


1 **Figure 2.**

2

a



b



3

4

5

6

7

8

9

10

11

12

13



14

15

1 **Figure 3.**

2

3



4

5

6

7

8

9

10

11

12


13

14

1 **Figure 4.**

2

3



4

5

6

7

8

9

10

11

12

13

14


15

1 **Figure 5.**


2

3

a



b



4

5

6

7

8

9

10

11

